Dutch government seizes control of Chinese-owned chipmaker Nexperia, sparking export ban and auto supply chain disruptions.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Profitable companies with consistent earnings growth outperform speculative 'story stocks' without profits, as highlighted by the strong EPS growth of firms like Maxim Global, Nippon Life, and Cholamandalam.
Dutch government seizes control of Chinese-owned chipmaker Nexperia, sparking export ban and auto supply chain disruptions.
Incyte advances multiple early-phase cancer trials with potential therapeutic breakthroughs, highlighting their strategic focus on oncology and rare diseases.
Profitable companies with consistent earnings growth outperform speculative 'story stocks' without profits, as highlighted by the strong EPS growth of firms like Maxim Global, Nippon Life, and Cholamandalam.
